Abingdon-On-Thames, England, United Kingdom, May 2024 – Kristoff Rademan has been appointed as the Chief Financial Officer at EnSilica, a role in which he will oversee the financial strategies and operations at the forefront of ASIC design and supply. Rademan’s extensive experience in finance within the tech and biopharma sectors is expected to drive significant growth and innovation at EnSilica.
Rademan brings a wealth of expertise to his new role, having previously served at Oxford Biomedica for over a decade. Most recently, he held the position of Vice President, Group Financial Controller from September 2019 to May 2024, where he played a pivotal role in enhancing financial controls and supporting the company’s expansion. His tenure at Oxford Biomedica also included positions as Group Financial Controller and Financial Controller, spanning from January 2013 to May 2024, where he contributed significantly to the company’s financial health and strategic planning.
Prior to his extensive service at Oxford Biomedica, Rademan was the Finance Director for UK & Ireland at Archimedes Pharma from August 2011 to January 2013. In this role, he was instrumental in steering the financial direction and strategies across the region. He also served as Group Finance Manager and European Finance Analyst at Archimedes Pharma, further solidifying his expertise in financial management within the pharmaceutical sector.
Before joining Archimedes Pharma, Rademan developed his foundational finance skills at KPMG LLP in Reading, UK, where he progressed from a Trainee Accountant to an Assistant Manager from January 2003 to October 2008.
About EnSilica: EnSilica is a distinguished fabless design house dedicated to custom ASIC design and supply, primarily serving OEMs and system houses across automotive, industrial, healthcare, and communications markets. The company boasts extensive capabilities in RF, mmWave, mixed signal, and digital ICs, complemented by a robust portfolio of core IP. Headquartered near Oxford, UK, EnSilica operates design centres in the UK, India, and Brazil and is listed on the London Stock Exchange’s AIM market under the ticker ENSI.
Read Also : Imagination in a Disrupted Age: Navigating the Future with Curiosity and Empathy
